References
- Klein A. W. Skin filling. Collagen and other injectables of the skin. Dermatol Clin 2001; 19: 491–508, ix
- Kligman A. M. Psychological aspects of skin disorders in the elderly. Cutis 1989; 43: 498–501
- Kligman A., Lavker R. Cutaneous aging: The differences between intrinsic aging and photoaging. J Cutan Aging and cosm. derm 1988; 1: 5–12
- Little J. W. Volumetric perceptions in midfacial aging with altered priorities for rejuvenation. Plast Reconstr Surg 2000; 105: 252–66, discussion 86–9
- Broder K. W., Cohen S. R. An overview of permanent and semipermanent fillers. Plast Reconstr Surg 2006; 118((3 suppl))7S–14S
- Klein A. W., Elson M. L. The history of substances for soft tissue augmentation. Dermatol Surg 2000; 26: 1096–105
- Barton S. E., Engelhard P., Conant M. Poly‐l‐lactic acid for treating HIV‐associated facial lipoatrophy: A review of the clinical studies. Int J STD AIDS 2006; 17: 429–35
- Vleggaar D. Soft‐tissue augmentation and the role of poly‐l‐lactic acid. Plast Reconstr Surg 2006; 118((3 suppl))46S–54S
- Lemperle G., Morhenn V., Charrier U. Human histology and persistence of various injectable filler substances for soft tissue augmentation. Aesthetic Plast Surg 2003; 27: 354–66, discussion 67
- Bergeret‐Galley C. Comparison of resorbable soft tissue fillers. Aesthetic Surg J 2004; 24: 33–46
- Pistner H., Gutwald R., Ordung R., Reuther J., Muhling J. Poly(l‐lactide): A long‐term degradation study in vivo. I. Biological results. Biomaterials 1993; 14: 671–7
- Gogolewski S., Jovanovic M., Perren S. M., Dillon J. G., Hughes M. K. Tissue response and in vivo degradation of selected polyhydroxyacids: Polylactides (PLA), poly(3‐hydroxybutyrate) (PHB), and poly(3‐hydroxybutyrate‐co‐3‐hydroxyvalerate) (PHB/VA). J Biomed Mater Res 1993; 27: 1135–48
- Sculptra ® Product Information. sanofi aventis; 2006. Accessed August 2007. URL: http://products.sanofi‐aventis.us/sculptra/sculptra.html.
- Kulkarni R. K., Pani K. C., Neuman C., Leonard F. Polylactic acid for surgical implants. Arch Surg 1966; 93: 839–43
- Tunc D., Jadhav B. Development of absorbable, ultra high strength poly(lactides). Am. Chem Soc 1990; 383–387, Meeting Sept. 1988
- Burgess C. M., Quiroga R. M. Assessment of the safety and efficacy of poly‐l‐lactic acid for the treatment of HIV‐associated facial lipoatrophy. J Am Acad Dermatol 2005; 52: 233–9
- Moyle G. J., Brown S., Lysakova L., Barton S. E. Long‐term safety and efficacy of poly‐l‐lactic acid in the treatment of HIV‐related facial lipoatrophy. HIV Med 2006; 7: 181–5
- Moyle G. J., Lysakova L., Brown S. A randomized open‐label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004; 5: 82–7
- Valantin M. A., Aubron‐Olivier C., Ghosn J. Polylactic acid implants (New‐Fill) to correct facial lipoatrophy in HIV‐infected patients: Results of the open‐label study VEGA. AIDS 2003; 17: 2471–7
- Lam S. M., Azizzadeh B., Graivier M. Injectable poly‐l‐lactic acid (Sculptra): Technical considerations in soft‐tissue contouring. Plast Reconstr Surg 2006; 118((3 suppl))55S–63S
- Lowe N. J., Maxwell C. A., Patnaik R. Adverse reactions to dermal fillers: Review. Dermatol Surg 2005; 31((11 Pt 2))1616–25
- Borelli C., Kunte C., Weisenseel P., Thoma‐Greber E., Korting H. C., Konz B. Deep subcutaneous application of poly‐l‐lactic acid as a filler for facial lipoatrophy in HIV‐infected patients. Skin Pharmacol Physiol 2005; 18: 273–8
- Vleggaar D., Bauer U. Facial enhancement and the European experience with Sculptra (poly‐l‐lactic acid). J Drugs Dermatol 2004; 3: 542–7
- Lowe N. J. Dispelling the myth: Appropriate use of poly‐l‐lactic acid and clinical considerations. J Eur Acad Dermatol Venereol 2006; 20((suppl 1))2–6